Soluble TNFR2 Analysis for Reproducible MSC Immunomodulatory Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for evaluating the immunomodulatory effects of mesenchymal stem cells (MSCs) in vivo are non-reproducible and variable, necessitating a standardized in vitro approach to assess their immunomodulatory activity.
Innovation Solution
A method involving culturing MSCs under basal and inflammatory conditions, measuring soluble TNFR2 protein levels, normalizing these levels with total protein content, and calculating an Inflammatory Stimulation Index (ISI) to determine immunomodulatory activity, with ISI >1 indicating responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional in vivo evaluation methods are used to assess immunomodulatory effects of MSCs, then clinical observation can be obtained, but substantial variability and non-reproducibility occur
Solution Approach 1:
The patent replaces complex in vivo clinical observation systems with a simplified in vitro biochemical measurement system. Specifically, it substitutes animal/human subject-based immunomodulatory effect evaluation with a cell culture system that measures soluble TNFR2 protein levels in supernatant, thereby achieving reproducible results without the variability inherent in living organism studies
Solution Approach 2:
The patent introduces soluble TNFR2 protein as an intermediary marker to indirectly assess immunomodulatory activity. Instead of directly measuring complex immunomodulatory effects in vivo, the method uses soluble TNFR2 levels in cell culture supernatant as a reliable proxy indicator, enabling reproducible evaluation through a measurable intermediate substance
2Measurement precision
If in vitro methods are developed to evaluate MSC immunomodulatory effects, then reproducibility improves, but measurement precision requirements increase
Solution Approach 1:
The patent transforms the measurement parameter from direct immunomodulatory effect assessment to soluble TNFR2 protein concentration measurement. By changing the measured parameter to a specific protein marker that can be quantified using ELISA or similar assays, the method achieves precise and reproducible measurements while simplifying the detection process
Solution Approach 2:
The patent creates an in vitro copy of the immunomodulatory interaction environment, allowing measurement of soluble TNFR2 release under controlled conditions. This copied system replicates the essential biochemical interactions without the complexity of in vivo variables, enabling precise measurement of immunomodulatory potential
3Productivity
If soluble TNFR2 levels are measured in culture supernatant, then immunomodulatory activity can be quantified, but normalization with total protein level is required to account for cell density variations
Solution Approach 1:
The patent employs a self-normalization approach where the system itself provides the reference standard. By measuring total protein content in the same cell culture system and using it to normalize soluble TNFR2 levels, the method creates an internal reference that automatically accounts for variations in cell number and culture conditions, eliminating the need for external calibration standards
Data Source
AI summary
The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.